Global Retinoblastoma Presentation and Analysis by National Income Level

Global Retinoblastoma Study Group

IMPORTANCE Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child’s life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale.

OBJECTIVES To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis.

DESIGN, SETTING, AND PARTICIPANTS A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017.

MAIN OUTCOMES AND MEASURES Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis.

RESULTS The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4%) were female. Most patients (n = 3685 [84.7%]) were from low- and middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 [62.8%]), followed by strabismus (n = 429 [10.2%]) and proptosis (n = 309 [7.4%]). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle-income countries and HICs, 17.92 [95% CI, 12.94-24.80], and for lower-middle-income countries vs upper-middle-income countries and HICs, 5.74 [95% CI, 4.30-7.68]).

CONCLUSIONS AND RELEVANCE This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs.
Retinoblastoma, the most common eye cancer of childhood, is fatal if left untreated. Prognosis of patients with retinoblastoma in high-income countries (HICs) has improved over the past 50 years, now reaching a near 100% disease-free survival rate. This is attributed to several factors, including (1) creation of specialized referral centers, (2) decoding of the genetic basis of the disease, (3) formation of screening programs, and (4) the introduction of chemotherapy. In HICs, retinoblastoma is a curable disease, and attention has now shifted to eye salvage and improvement of quality of life. In low- and middle-income countries (LMICs), where more than 80% of global retinoblastoma cases arise, the prognosis is poor, and it is assumed that this is because of delayed diagnosis and treatment. Publications from LMICs are scarce, and many countries do not report their retinoblastoma data. The stage of retinoblastoma at the time of diagnosis in low-income, middle-income, and high-income countries has not been surveyed globally. This information is important for policy and health care planning at national and international levels.

The objectives of this study are to (1) report the stage at diagnosis in a large global sample of patients with retinoblastoma, (2) examine associations between clinical variables at diagnosis in a large global sample of patients with retinoblastoma, at least by means of enucleation, were eligible to participate.

Methods

This study originated from a consortium of retinoblastoma treatment centers in 8 countries on 3 continents. From June 2017 through December 2018, all known retinoblastoma treatment centers across the world were contacted by means of personal communications, presentations at scientific conferences, and linking to professional societies in the fields of ophthalmology and oncology to form a global network. All centers involved in the diagnosis and treatment of patients with retinoblastoma, at least by means of enucleation, were eligible to participate.

Study Design

This study adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines. It was a 1-year cross-sectional analysis that included all treatment-naive patients with retinoblastoma who presented to participating centers from January 1, 2017, to December 31, 2017, and who were treated or offered treatment for retinoblastoma. A predesigned form was used for data collection (eTable 1 in the Supplement). The data collected included country of residence, sex, first ocular symptom as noted by parents, age at first indication of symptom, age and ocular indication at presentation to the retinoblastoma treatment center, laterality, familial history of retinoblastoma, staging according to the American Joint Committee on Cancer Staging Manual, Eighth Edition and the International Retinoblastoma Staging System, and primary treatment. Data on country of residence, sex, and laterality were minimum criteria for patient enrollment. The staging classifications were simplified to include only the major subcategories (eTable 2 in the Supplement). For the primary tumor site (cT), the eye with the more advanced disease was used for analysis. Completed forms were electronically uploaded onto a secure server, after which a data quality assurance process was performed (eMethods in the Supplement).

The study was approved by the institutional review board at the London School of Hygiene & Tropical Medicine, which granted a waiver of patient informed consent. Participating centers applied for and received ethics clearance in their countries according to local institutional guidelines.

Statistical Analysis

All analyses were performed using R software, version 3.5.2 (R Foundation for Statistical Computing), and IBM SPSS Statistics, version 25.0 (IBM Corp). The crude birth rate, country population size, and country classification by national income level were obtained from the 2017 World Population Prospects. The predicted number of new patients with retinoblastoma per country was calculated as follows: [country population × crude birth rate/1000/17,000], and predicted number per national income level was the sum result of all countries at the same level.

Unless otherwise indicated, summary statistics are presented as median and interquartile range (25%-75%). The t test was used to compare means of normally distributed continuous variables, Fisher exact and Pearson χ² tests were used to compare categorical variables, Spearman rank correlation test was used for nonnormal continuous and ordinal variables, and the Cochran-Armitage test was used to test for trend in the proportions of patients with a given parameter across the income levels. Binomial logistic regression was used to model the effect of income level (upper-middle-income level and high-income level combined), presentation age (grouped by tertiles), familial retinoblastoma history, sex, and bilateral, on the likelihood of children having advanced disease (cT4) at presentation. An α level of .05 and 2-tailed P values were used to determine statistical significance.

Results

The study sample included 4351 treatment-naïve patients with retinoblastoma residing in 153 countries (Figure). The data analyzed by national income level are shown in Table 1. Country-level and continent-level data are shown at http://globalretinoblastoma.org (password: Ret2017).
of advanced disease (ie, proptosis, swollen eyelids, red eye) was reported in 487 (11.7%) patients. A higher income level was associated with a lower proportion of patients with symptoms of advanced disease ($z$ score = 10.9, dim = 4; $P < .001$; additional analysis is provided in eTable 4 in the Supplement).

Symptoms at Time of Diagnosis at Retinoblastoma Centers
Of all patients, 2998 (70.4%) presented with either leukocoria, strabismus, or a combination of these symptoms (eTable 3 in the Supplement). In LICs, combinations of proptosis, red eye, orbital cellulitis, and extraocular retinoblastoma (ie, advanced disease) were present in 248 (46.7%) patients. Analysis of patients who had only leukocoria and/or strabismus (ie, early disease) as the symptoms noticed by the parents, but who presented to retinoblastoma treatment centers with symptoms of advanced disease, showed a significantly larger proportion coming from LICs ($z$ score = 18.4, dim = 4; $P < .001$; additional analysis is provided in eTable 4 in the Supplement).

Age at Diagnosis
The overall median age at diagnosis was 23.5 months (interquartile range [IQR], 11.2-36.5 months; Table 1). The median age at diagnosis of patients from LICs was 30.5 months (IQR, 18.3-45.9 months) compared with 14.0 months (IQR, 6.2-26.6 months) for patients from HICs. There was a significant association between presentation age and national income level, with children in LMICs presenting at an older age (eTable 5 in the Supplement).

Tumor Staging
Globally, the most common cTNM stages were cT3 ($n = 1933$ of 4114 [47.0%]), N0 ($n = 3303$ of 4281 [77.2%]), and M0 ($n = 3964$ of 4275 [92.7%]) (Table 1). Extraocular retinoblastoma at time of diagnosis was reported in 926 of 4302 (21.5%) patients (256 [49.1%] in LICs vs 10 [1.5%] in HICs). Distant metastases were reported in 94 (18.9%), 157 (8.3%), 58 (4.8%), and 2 (0.3%) patients from low, lower-middle, upper-middle, and high income-level countries, respectively ($z$ score = 11.9, dim = 4; $P < .001$). Higher economic grouping was associated with higher proportions of intraocular and earlier stage disease at diagnosis (Table 1).

Risk Factors for Advanced Disease at Time of Diagnosis
Sex ($\chi^2 = 1.016$; $P = .31$), bilaterality ($\chi^2 = 0.830$; $P = .36$) and familial history of retinoblastoma ($\chi^2 = 2.269$; $P = .13$) were found to be nonsignificant factors for the prediction of cT4 category (extraocular retinoblastoma) and hence were removed from the model. On logistic regression, low-income level and older presentation age were found to be independent and significant predictive factors for advanced disease (Table 2).

Familial History and Bilateral Retinoblastoma
Familial history of retinoblastoma was reported in 199 of 4215 (4.7%) patients (15 [3.1%], 75 [4.0%], 54 [4.5%], and 55 [8.4%] patients from low, lower-middle, upper-middle, and high income-level countries, respectively). Bilateral disease at time of diagnosis was seen in 1341 of 4351 (30.8%) patients (125 [23.5%], 615 [31.7%], 365 [30.1%], and 236 [35.4%] patients from low, lower-middle, upper-middle, and high income-level countries, respectively.

Geographic and Socioeconomic Characteristics
More than half (2276 [52.3%]) of the patients were from Asia, 1024 (23.5%) were from Africa, 522 (12.0%) were from Europe, 512 (11.8%) were from the Americas, and 17 (0.4%) were from Oceania. Of all patients, 533 (12.3%) came from low-income countries (LICs), 1940 (44.6%) from lower-middle, 1212 (27.9%) from upper-middle, and 666 (15.3%) from HICs.

Completeness of Data
For 4116 (94.6%) of the study patients, data were reported on each study parameter, except for age at first ocular symptom of retinoblastoma (2175 [50.0%]; not included in the analysis). Analysis by national income level showed that reporting was nearly complete (≥98.5%) for patients from high-income and upper-middle-income countries, and more than 94.1% and 89.1% for patients from low, lower-middle, upper-middle, and high income–level countries, respectively.

Symptoms Leading to Referral
The most common first symptom of disease was leukocoria ($n = 2175$ [50.0%]; not included in the analysis). Additional symptoms followed by strabismus ($n = 429$ [10.2%]), with a further 162 (3.9%) patients having a combination of leukocoria and strabismus (eTable 3 in the Supplement). Proptosis was reported in 309 (7.4%) patients. At least 1 symptom of advanced disease (ie, proptosis, swollen eyelids, red eye) was reported in 487 (11.7%) patients. A higher income level was associated with a lower proportion of patients with symptoms of advanced disease ($z$ score = 10.9, dim = 4; $P < .001$; additional analysis is provided in eTable 4 in the Supplement).

Figure. Cohort Recruitment Flowchart

- **Center recruitment**: 298 Retinoblastoma centers from 134 countries were contacted
  - 6 Centers were excluded because they had no patients with retinoblastoma in 2017
  - 6 Centers were excluded because they had new patients with retinoblastoma in 2017 but did not report the patients to this study
  - 8 Centers were excluded because they had no information available on patients with retinoblastoma in 2017

- **Patient enrollment**: 278 Retinoblastoma centers from 130 countries joined the study and reported 4195 new patients with retinoblastoma from 153 countries
  - 14 Patients were excluded owing to duplicate reporting
  - 30 Patients were excluded because they did not fulfill the inclusion criteria

- **4351 Patients from 153 countries were eligible**

  a Patients from 23 countries with no retinoblastoma centers were treated outside of their country of residence.

  b Inclusion criteria included reporting of country of residence, sex, and laterality. Patients for whom 1 or more of these parameters were not available were not included in the analytic sample.

- **Completeness of Data**: For 4116 (94.6%) of the study patients, data were reported on each study parameter, except for age at first ocular symptom of retinoblastoma (2175 [50.0%]; not included in the analysis). Analysis by national income level showed that reporting was nearly complete (≥98.5%) for patients from high-income and upper-middle-income countries, and more than 94.1% and 89.1% for patients from low-middle-income countries and LICs, respectively.

- **Symptoms at Time of Diagnosis at Retinoblastoma Centers**: Of all patients, 2998 (70.4%) presented with either leukocoria, strabismus, or a combination of these symptoms (eTable 3 in the Supplement). In LICs, combinations of proptosis, red eye, orbital cellulitis, and extraocular retinoblastoma (ie, advanced disease) were present in 248 (46.7%) patients. Analysis of patients who had only leukocoria and/or strabismus (ie, early disease) as the symptoms noticed by the parents, but who presented to retinoblastoma treatment centers with symptoms of advanced disease, showed a significantly larger proportion coming from LICs ($z$ score = 18.4, dim = 4; $P < .001$; additional analysis is provided in eTable 4 in the Supplement).

- **Age at Diagnosis**: The overall median age at diagnosis was 23.5 months (interquartile range [IQR], 11.2-36.5 months; Table 1). The median age at diagnosis of patients from LICs was 30.5 months (IQR, 18.3-45.9 months) compared with 14.0 months (IQR, 6.2-26.6 months) for patients from HICs. There was a significant association between presentation age and national income level, with children in LMICs presenting at an older age (eTable 5 in the Supplement).

- **Tumor Staging**: Globally, the most common cTNM stages were cT3 ($n = 1933$ of 4114 [47.0%]), N0 ($n = 3303$ of 4281 [77.2%]), and M0 ($n = 3964$ of 4275 [92.7%]) (Table 1). Extraocular retinoblastoma at time of diagnosis was reported in 926 of 4302 (21.5%) patients (256 [49.1%] in LICs vs 10 [1.5%] in HICs). Distant metastases were reported in 94 (18.9%), 157 (8.3%), 58 (4.8%), and 2 (0.3%) patients from low, lower-middle, upper-middle, and high income-level countries, respectively ($z$ score = 11.9, dim = 4; $P < .001$). Higher economic grouping was associated with higher proportions of intraocular and earlier stage disease at diagnosis (Table 1).

- **Risk Factors for Advanced Disease at Time of Diagnosis**: Sex ($\chi^2 = 1.016$; $P = .31$), bilaterality ($\chi^2 = 0.830$; $P = .36$) and familial history of retinoblastoma ($\chi^2 = 2.269$; $P = .13$) were found to be nonsignificant factors for the prediction of cT4 category (extraocular retinoblastoma) and hence were removed from the model. On logistic regression, low-income level and older presentation age were found to be independent and significant predictive factors for advanced disease (Table 2).

- **Familial History and Bilateral Retinoblastoma**: Familial history of retinoblastoma was reported in 199 of 4215 (4.7%) patients (15 [3.1%], 75 [4.0%], 54 [4.5%], and 55 [8.4%] patients from low, lower-middle, upper-middle, and high income-level countries, respectively). Bilateral disease at time of diagnosis was seen in 1341 of 4351 (30.8%) patients (125 [23.5%], 615 [31.7%], 365 [30.1%], and 236 [35.4%] patients from low, lower-middle, upper-middle, and high income-level countries, respectively).
Table 1. Clinical Characteristics at Presentation of 4351 New Patients With Retinoblastoma Diagnosed in 2017

<table>
<thead>
<tr>
<th>Parameter</th>
<th>National Income Level (No. [% within the national income level]) [% within the evaluated parameter]</th>
<th>Total, No. [%]</th>
<th>Significance</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis, median (IQR), mo</td>
<td>Total sample</td>
<td>30.5 (18.3-45.9)</td>
<td>24.4 (12.2-37.3)</td>
<td>20.7 (10.1-33.8)</td>
</tr>
<tr>
<td></td>
<td>Unilateral</td>
<td>35.0 (22.2-48.0)</td>
<td>29.1 (18.1-42.9)</td>
<td>25.5 (12.9-37.6)</td>
</tr>
<tr>
<td></td>
<td>Bilateral</td>
<td>22.9 (11.8-32.8)</td>
<td>14.4 (8.0-25.8)</td>
<td>11.4 (6.0-21.0)</td>
</tr>
<tr>
<td>Reported cases, No. (%)</td>
<td>524/533 (98.3)</td>
<td>1909/1940 (98.4)</td>
<td>1192/1212 (98.3)</td>
<td>664/666 (99.7)</td>
</tr>
<tr>
<td>Laterality at diagnosis&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Unilateral</td>
<td>408 (76.5) [11.6]</td>
<td>1325 (68.3) [44.0]</td>
<td>847 (69.9) [28.1]</td>
</tr>
<tr>
<td></td>
<td>Bilateral</td>
<td>125 (23.5) [9.3]</td>
<td>615 (31.7) [45.9]</td>
<td>365 (30.1) [27.2]</td>
</tr>
<tr>
<td>Familial history of retinoblastoma</td>
<td>No</td>
<td>467 (96.9) [11.6]</td>
<td>1805 (96.0) [44.9]</td>
<td>1141 (95.5) [28.4]</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>15 (3.1) [7.5]</td>
<td>75 (4.0) [37.7]</td>
<td>54 (4.5) [27.1]</td>
</tr>
<tr>
<td>Total, No. (%)</td>
<td>482/533 (90.4)</td>
<td>1880/1940 (95.9)</td>
<td>1199/1212 (98.6)</td>
<td>658/666 (98.2)</td>
</tr>
<tr>
<td>Primary tumor</td>
<td>cT1</td>
<td>5 (1.0) [1.8]</td>
<td>96 (5.1) [35.3]</td>
<td>67 (6.1) [24.6]</td>
</tr>
<tr>
<td></td>
<td>cT2</td>
<td>62 (12.6) [4.9]</td>
<td>406 (21.7) [31.8]</td>
<td>482 (44.1) [37.8]</td>
</tr>
<tr>
<td></td>
<td>cT3</td>
<td>209 (42.6) [10.8]</td>
<td>1013 (54.1) [52.4]</td>
<td>488 (44.6) [25.2]</td>
</tr>
<tr>
<td></td>
<td>cT4</td>
<td>215 (43.8) [14.0]</td>
<td>359 (19.2) [56.7]</td>
<td>56 (5.1) [8.8]</td>
</tr>
<tr>
<td>Total, No. (%)</td>
<td>491/533 (92.1)</td>
<td>1874/1940 (96.6)</td>
<td>1093/1212 (90.2)</td>
<td>656/666 (98.5)</td>
</tr>
<tr>
<td>Regional lymph node</td>
<td>N0</td>
<td>105 (20.7) [12.6]</td>
<td>350 (18.4) [42.1]</td>
<td>267 (22.2) [32.1]</td>
</tr>
<tr>
<td></td>
<td>N1</td>
<td>360 (71.0) [10.9]</td>
<td>1475 (77.3) [44.7]</td>
<td>912 (75.9) [27.6]</td>
</tr>
<tr>
<td>Total, No. (%)</td>
<td>498/533 (89.1)</td>
<td>1906/1940 (98.2)</td>
<td>1202/1212 (99.2)</td>
<td>665/666 (99.8)</td>
</tr>
<tr>
<td>Distant metastasis</td>
<td>M0</td>
<td>404 (81.1) [10.2]</td>
<td>1749 (91.8) [44.1]</td>
<td>1147 (95.2) [28.9]</td>
</tr>
<tr>
<td></td>
<td>M1</td>
<td>65 (13.1) [30.4]</td>
<td>110 (5.8) [31.8]</td>
<td>482 (44.1) [37.8]</td>
</tr>
<tr>
<td>Total, No. (%)</td>
<td>507/533 (95.1)</td>
<td>1907/1940 (98.3)</td>
<td>1202/1212 (99.2)</td>
<td>665/666 (99.8)</td>
</tr>
<tr>
<td>Hereditary trait</td>
<td>HK</td>
<td>360 (72.7) [14.2]</td>
<td>1211 (63.8) [47.9]</td>
<td>736 (61.6) [29.1]</td>
</tr>
<tr>
<td></td>
<td>H0</td>
<td>0</td>
<td>44 (2.3) [17.3]</td>
<td>59 (4.9) [23.2]</td>
</tr>
<tr>
<td>Total, No. (%)</td>
<td>495/533 (92.9)</td>
<td>1898/1940 (97.8)</td>
<td>1195/1212 (98.6)</td>
<td>662/666 (99.4)</td>
</tr>
<tr>
<td>Extracocular retinoblastoma</td>
<td>No</td>
<td>265 (50.9) [7.8]</td>
<td>1393 (73.0) [41.3]</td>
<td>1062 (88.0) [31.5]</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>256 (49.1) [27.6]</td>
<td>517 (26.0) [55.6]</td>
<td>145 (12.0) [15.7]</td>
</tr>
<tr>
<td>Total, No. (%)</td>
<td>521/533 (97.7)</td>
<td>1908/1940 (98.4)</td>
<td>1207/1212 (99.6)</td>
<td>666/666 (100)</td>
</tr>
</tbody>
</table>

Abbreviations: IQR, interquartile range; NA, not applicable.

<sup>a</sup> Spearman rank correlation.
<sup>b</sup> Inclusion criteria: 100% reporting.
<sup>c</sup> Fisher exact test for proportion of bilateral cases.
<sup>d</sup> Cochran-Armitage test for proportion of familial history of retinoblastoma.
<sup>e</sup> Cochran-Armitage test for proportion of cT3 or greater.
<sup>f</sup> Cochran-Armitage test for proportion of cases with lymph node involvement.
<sup>g</sup> Cochran-Armitage test for proportion of cases with distant metastasis.
<sup>h</sup> Cochran-Armitage test for proportion of cases with extracocular disease.
The factors causing delay in retinoblastoma diagnosis and treatment in LMICs are beyond the scope of this study. However, the findings here suggest that late recognition of signs of retinoblastoma, as well as delay in reaching a dedicated retinoblastoma treatment center once ocular symptoms have been detected, likely play a role, and both factors are associated with national income level. These findings indicate clinically significant progression of signs between parental detection and presentation to a specialist center in LMICs. Earlier recognition of leukocoria or strabismus and urgent referral for diagnosis is very important if children are to receive treatment before extraocular spread occurs.

A familial history of retinoblastoma followed the same pattern, with relatively fewer cases in lower-income countries. A possible explanation could be underreporting or inadequate medical record keeping in resource-limited settings. However, a more plausible explanation would be that children with familial history of disease are diagnosed and treated early in HICs so that they survive to childbearing age, whereas this may not be the case in LMICs.

Nearly all essential diagnostic and therapeutic modalities were available in most participating treatment centers. Enucleation surgery, which was available in all treatment centers, can save lives, and intravenous chemotherapy, which was available for 98.0% of the patients in this study, can save lives and also result in globe salvage if patients are diagnosed and treated in time.27,28

The results of this study point to an urgent need to improve retinoblastoma detection and access to treatment in LMICs. Several initiatives are addressing this challenge by implementing twinning programs that link centers from higher-resource and lower-resource countries.12,29-32 However, there is a pressing need for coordinated action on a global level. In a rare yet curable cancer such as retinoblastoma, with approximately 8000 new patients annually worldwide, such an action is feasible to make retinoblastoma a zero-death cancer.33

The World Health Organization Global Initiative for Childhood Cancer aims to raise survival for key childhood cancers, including retinoblastoma, to 60% by the year 2030 by helping health systems in LMICs integrate childhood cancer into their national strategies and improve their capacity to diagnose and deliver curative treatment.34 In this context, accurate retinoblastoma-specific data are essential. The results of this study serve as a report of the current retinoblastoma presentation status, against which future interventions can be measured, and demonstrate the need for a strong global partnership to improve outcomes for patients with retinoblastoma everywhere.
Results of the present study showed that older age at presentation and, independently, national income level were associated with advanced disease, which suggests that other factors besides age may be important in disease progression. It has been suggested that infection by the human papillomavirus, which is more prevalent in LMICs, is associated with the development of nonhereditary retinoblastoma, and it is possible that this could be associated with more aggressive disease behavior. Another possible explanation relates to the genetic landscape of retinoblastoma and particularly retinoblastoma, and it is possible that this could be associated with more aggressive disease behavior. Another possible explanation relates to the genetic landscape of retinoblastoma and especially to cases with no RBP mutation but a high level of amplification of the oncogene MYCN. These cases are unilateral, develop at an early age, and show aggressive features. They were found only in 1.4% of unilateral retinoblastoma cases, all from Europe, and they may be associated with more aggressive disease behavior. This was confirmed by the above-mentioned hypotheses. However, these speculations await further studies.

Limitations
This study has several limitations. First, it included a convenience sample and therefore had an inherent potential bias. Nevertheless, to our knowledge, this is the largest and most geographically comprehensive study in the field of retinoblastoma, and we believe its findings can be generalized. Second, data collection was mostly retrospective, with the exception of treatment centers that presented in lower-income countries is not entirely explained by older age. Further research is warranted to investigate what factors other than age play a role in disease progression in low-income settings. Prompt action at national and international levels is warranted to improve health education about retinoblastoma, as well as access to early diagnosis and treatment in retinoblastoma treatment centers in LMICs.

Conclusions
The findings of this cross-sectional global analysis of retinoblastoma at the time of diagnosis revealed important differences in presentation among patients from different countries, depending on their national income level. Patients with retinoblastoma from HICs present with early disease and are, therefore, likely to survive. In contrast, patients from lower-income settings present with late disease, many with extracocular extension and some already with metastasis, and their prognosis is poorer. A familial history of retinoblastoma is relatively uncommon in lower-income countries, likely owing to death related to late-disease presentation before childbearing years. A surprise finding of this study is that more advanced disease at presentation in lower-income countries is not entirely explained by older age. Further research is warranted to investigate what factors other than age play a role in disease progression in low-income settings. Prompt action at national and international levels is warranted to improve health education about retinoblastoma, as well as access to early diagnosis and treatment in retinoblastoma treatment centers in LMICs.
Global Retinoblastoma Presentation and Analysis by National Income Level

Katherine E. Paton, MD, FRCSC; Katarzyna FRCOphth; Claudia R. Pascual Morales, MD; Parrozzani, MD, PhD; Manoj Parulekar, MS, FRCOphth; Vivian Paintsil, FWACP; Luisa Paiva, MD; Halimah Pagarra, MD, PhD; Sally L. Painter, FWASC, FAEH; Andrzej Olechowski, MD; Scott C. N. Obono-Obiang, MD; Ngozi C. Oguego, MB, BS, FCOPth, MBB; MCS; Othman A. O. Ziko, MD, PhD; Maria Zonderman, MBA, Richard Bowman, FRCOphth.

Affiliations of The Global Retinoblastoma Study Group Authors: International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom (Fabian, Astbury, Bascarain, Foster, Zonderman, Bowman); The Goldschlğer Eye Institute, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel (Fabit, Prat, Vishnevskia-Dai); Ophthalmology Department of Rabat, Mohammed V University, Rabat, Morocco (Abdallah); Aminu Kano Teaching Hospital, Bayero University, Kano, Nigeria (Adbullahi, Sadiqu Hassan, Umar); Basa Children’s Specialty Hospital, Basa, Iraq (Abdulqader, Al-Shaheen); National Hospital of Namey, Niaray, Niger (Adamou Boubacar); University of Iliori Teaching Hospital, University of Iliori, Ilorin, Nigeria (Ademola-Popoola); Department of Ophthalmology, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria (Adelaja); University of California, San Francisco (Afshar, S. Rahman); Department of Pediatrics, Banaras Hindu University, Varanasi, India (Agarwal); Department of Ophthalmology, College of Medicine, University of Nigeria, Enugu, Nigeria (Aghaji, Oguoeg); The Children’s Hospital and the Institute of Child Health, Lahore, Pakistan (Ahmad, Mushtaq, Qayum); RS Dr Wahidin Sudirohusodo, Makassar, Indonesia (Aikb, Pagara); The Royal London Hospital, Barts Health NHS Trust, and Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom (Al, Inarby, Reed); Hawler Medical University, Erbil, Iraq (Al, Abadi, Al-Kadiri, Reddy); Pediatric Ophthalmology Unit, Children Welfare Teaching Hospital, College of Medicine, University of Baghdad, Baghdad, Iraq (Al, Abadi, Al-Kadiri, Reddy), Rabat, Moulay Hassan University, Rabat, Morocco (Al-Harby, Reddy); Hawler Medical University, Erbil, Iraq (Al, Abadi, Al-Kadiri, Reddy), Rabat, Moulay Hassan University, Rabat, Morocco (Al-Harby, Reddy); Hawler Medical University, Erbil, Iraq (Al, Abadi, Al-Kadiri, Reddy), Rabat, Moulay Hassan University, Rabat, Morocco (Al-Harby, Reddy); Hawler Medical University, Erbil, Iraq (Al, Abadi, Al-Kadiri, Reddy), Rabat, Moulay Hassan University, Rabat, Morocco (Al-Harby, Reddy); Hawler Medical University, Erbil, Iraq (Al, Abadi, Al-Kadiri, Reddy), Rabat, Moulay Hassan University, Rabat, Morocco (Al-Harby, Reddy); Hawler Medical University, Erbil, Iraq (Al, Abadi, Al-Kadiri, Reddy), Rabat, Moulay Hassan University, Rabat, Morocco (Al-Harby, Reddy); Hawler Medical University, Erbil, Iraq (Al, Abadi, Al-Kadiri, Reddy), Rabat, Moulay Hassan University, Rabat, Morocco (Al-Harby, Reddy); Hawler Medical University, Erbil, Iraq (Al, Abadi, Al-Kadiri, Reddy), Rabat, Moulay Hassan University, Rabat, Morocco (Al-Harby, Reddy); Hawler Medical University, Erbil, Iraq (Al, Abadi, Al-Kadiri, Reddy), Rabat, Moulay Hassan University, Rabat, Morocco (Al-Harby, Reddy); Hawler Medical University, Erbil, Iraq (Al, Abadi, Al-Kadiri, Reddy), Rabat, Moulay Hassan University, Rabat, Morocco (Al-Harby, Reddy); Hawler Medical University, Erbil, Iraq (Al, Abadi, Al-Kadiri, Reddy), Rabat, Moulay Hassan University, Rabat, Morocco (Al-Harby, Reddy); Hawler Medical University, Erbil, Iraq (Al, Abadi, Al-Kadiri, Reddy), Rabat, Moulay Hassan University, Rabat, Morocco (Al-Harby, Reddy).
Department of Ophthalmology, Davidoff Center for Oncology, Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Israel; School of Medicine and Dentistry, Kong-Bu Teaching Hospital, University of Ghana, Accra, Ghana (Renner); University of Pretoria, Pretoria, South Africa (Reynolds, Schoeman); Federal Medical Center, Yola, Nigeria (Ribadu); Nampula Central Hospital, Nampula, Mozambique (Rhieva); Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria (Ritter-Sovinz); Children’s Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon (Saab); NIH Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital, London, United Kingdom (Sagoo); Department of Ophthalmology, University Medical Center, Ain Shams University, Cairo, Egypt (Said, Ziko); Hospital Dr Manuel Ascencio Villarreal, Cochabamba, Bolivia (Salas); Pediatric Ophthalmology, College of Physicians and Surgeons of New York, New York, New York (Shah); Department of Ophthalmology, Rasool Akram Hospital, Tehran, Iran (Sedaghat); Department of Ophthalmology, Center National d’Oncologie, Nouakchott, Mauritania (Djir); Division of Ophthalmology, Faculty of Medicine, Kyungpook National University, Daegu, South Korea (Shin); Department of Ophthalmology, Seoul National University, Seoul, South Korea (Shin); Department of Ophthalmology, University Medical Center, Halle, Germany (Stocker); Department of Ophthalmology, Hospital de Clínicas, Montevideo, Uruguay (Stöcklin); Department of Ophthalmology, Instituto Oncológico de Petrobras, Rio de Janeiro, Brazil (Stok); Children’s Hospital, Children’s Hospital, Seoul, South Korea (Stok).


